MarketVIEW: Japanese encephalitis vaccines

  • January 2012
  • -
  • VacZine Analytics Group Of Assay Advantage Ltd

Japanese encephalitis (JE) is an enzootic mosquito-borne viral disease where humans are incidental “dead end” hosts. JE currently affects countries of SE Asia and Western Pacific where around 3 billion people are considered at risk. The disease mainly affects children (< 15yrs) in poor rural areas where it can result in 25% mortality (est 10,000 deaths/yr) or residual neuropsychiatric sequelae (30% of cases). There are no specific treatments for JE.

This MarketVIEW product is comprised of a comprehensive MS Excel-based model(s) + Summary executive presentation which forecast the potential commercial value of Japanese Encephalitis vaccine(s) across endemic and markets to 2030. The model(s) contain value ($ m) and volume (mio doses) predictions for endemic countries in all age segments in both the public and private sector down to vaccine type. LO, BASE & HI forecast scenarios model expected demand from newly adopting countries as postulated by the PATH JE project.

THIS PRODUCT IS A SUMMARY PRESENTATION + ONE MODEL

Table Of Contents

Contents - Summary presentation (MS PowerPoint based)

Contents
Authors note
Executive summary
Commercial model: key outputs
JE vaccine: available market (endemic/public) ($ 000s) - all children to 2030
JE vaccine: available market (endemic/public) ($ 000s) - infants to 2030
JE vaccine: available market (endemic/public) ($ 000s) - 1 to 15 yrs to 2030
JE vaccine: endemic segment volume analysis (mio doses/yr)
JE vaccine: available market (endemic/private) ($ 000s) - 1 to 15 yrs to 2030
JE vaccine: market by vaccine type 2015
JE vaccines: all market segments, revenues/yr (2015)
JE: disease background
JE: transmission cycle
JE: geographic distribution
JE: epidemiology
JE: genotype distribution
JE: country reporting/surveillance
JE: WHO reported cases 2006 - 2010
JE: disease profile of main endemic countries
Risk of JE by country, region and season
DALYs per 100,000 persons in JE endemic countries
JE: disease trends and dynamics
JE: factors contributing to increasing transmission
JE and travelers
JE: control and prevention
JE control: aligned with major stakeholder objectives
PATH JE project: strategic goals
JE vaccines: policy evolution
JE vaccines: immunological aspects
Impact of JE vaccination
JE vaccination and cost effectiveness
Currently licensed JE vaccines (endemic)
Country status of JE control through immunization
Country use of JE vaccine types: SEA region
Country use of JE vaccine types: WPR region
JE focus on India
India: cases and deaths 1993 - 2009
India - JE priority districts
India - mass vaccination campaigns
India - mass vaccination campaigns: progress to date
Transition to new JE vaccines
Availability of new JE vaccines
JE vaccination: country future planning - SEA region
JE vaccination: country future planning - WPR region
Commercial model: detailed assumptions per WHO region/country
JE vaccine demand forecast: countries modelled
JE vaccines: modelling strategy
Commercial model assumptions - SEA region
Commercial model assumptions - WPR region
Pricing case studies for endemic vaccines
JE vaccine prices used in model
Source material
JE vaccines (PATH): estimated implementation 2006 - 2015
Timeline of JE in Thailand 1971 - 2006
Japan: immunization schedule 2011 (Japan: JEV vaccinations given 1995 - 2009 (000s)
Ensebakku subcutaneous JE vaccine: History of development
Ixiaro/JESPECT - distribution structure
Bibliography
About VacZine Analytics
Disclaimer
Back page

PAGES: 81 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents - Vaccine demand model (MS Excel-based) - endemic markets (public/private)

Title sheet
CHARTS - VAL (private)
CHARTS - VAL (pub)
CHARTS - VOL (pub)
GRAND VALUE SUMMARY
Value by vaccine type
Value Summary (pub Value Summary (pub 1-15 yrs)
Value Summary (priv 0 - 15 yrs)
Global price summary
Volume Summary (pub Volume Summary (pub 1-15 yrs)
Volume Summary (priv 0 - 15 yrs)
Volume Summaries
SEA region
Bangladesh (pub)
Bangladesh (priv)
Bhutan (pub)
Bhutan (priv)
India (pub)
India (priv)
Indonesia (pub)
Indonesia (priv)
Korean DPR (pub)
Timor Leste (pub)
Timor Leste (priv)
Myanmar (pub)
Myanmar (priv)
Nepal (pub)
Nepal (priv)
Pakistan (pub)
Pakistan (priv)
Sri Lanka (pub)
Sri Lanka (priv)
Thailand (pub)
Thailand (priv)
WPR region =>
Australia (pub)
Brunei (pub)
Brunei (priv)
Cambodia (pub)
Cambodia (priv)
China (pub)
Taiwan (pub)
Japan (pub)
Korea - republic (pub)
LAO PDR (pub)
LAO PDR (priv)
Malaysia (pub)
Malaysia (priv)
Papua New Guinea (pub)
Papua New Guinea (priv)
Philippines (pub)
Philippines (priv)
Russia FE (pub)
Russia FE (priv)
Vietnam (pub)
Epidemiology =>>
Endemic countries
JEV number of cases
Population databases
Birth cohorts - SEA
2 - 49 yrs SEA
Birth cohorts - WPR
2 - 49 yrs WPR
JEV - Japan data
Urban/rural split
Measles vaccine prices
Back page

WORKSHEETS: ~65

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023

  • $ 9 995
  • Industry report
  • March 2014
  • by Global Data

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023 Summary The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected ...

Antibiotics: Technologies and Global Markets

Antibiotics: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Identify the major market trends and the factors driving or inhibiting the growth of the global pharmaceutical antibiotics market and its various submarkets. - Learn about developments ...

Antifungal Drugs : Technologies and Global Markets

Antifungal Drugs : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This report aims to determine the current status of the global human antifungal market and assess its growth potential over the five-year period from 2013 through 2018. It covers approved human therapeutics ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.